Cochlear Limited (ASX:COH): FY26 Earnings, Implant Sales and Clinical Research Update

Aditi Sarkar

22 October 2026 04:20 PM AEDT

Cochlear Limited (ASX:COH): FY26 Earnings, Implant Sales and Clinical Research Update

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Cochlear Limited (ASX:COH) reported FY26 sales revenue of AUD 2,343.4 million, down 1% on a reported basis.
FY26 underlying net profit fell 22% to AUD 322.4 million; statutory profit was AUD 147.3 million.
Cochlear implant units increased 5% to 56,692; Services sales reached AUD 634.9 million.
September research update confirmed completion of recruitment in two fully implantable hearing-system pivotal studies.

Cochlear Limited (ASX:COH) develops implantable hearing technologies, including cochlear implants, sound processors and acoustic implant systems for people with hearing loss. On 22 October 2026, Cochlear Limited (ASX:COH) was priced at AUD 141.265, down 0.15% during the trading session. Its August FY26 results documented lower earnings despite higher implant unit volumes, while a September clinical update outlined progress in research into a fully implantable hearing system.

Company Business

Cochlear Limited (ASX:COH) reports three product-related revenue streams: cochlear implants, Services and Acoustics. Cochlear implants include the Nucleus Nexa system; Services comprises replacement sound processors, accessories and related products. The Acoustics portfolio includes the Osia system. Operations span developed and emerging healthcare markets, with revenue influenced by reimbursement arrangements, clinical referrals, hospital capacity and the mix of devices sold.

The company manufactures and develops medical devices while supporting clinicians and recipients after implantation. Cochlear Limited (ASX:COH) reported that Nexa accounted for more than 95% of implant sales in developed markets by June 2026. That measure reflects the mix of implants sold in those markets, rather than company-wide revenue growth.

Recent Development

In September 2026, Cochlear announced that recruitment had finished for its ELEVATE and ENTERPRISE pivotal studies of investigational fully implantable hearing technology. Together, the studies enrolled 92 adults, with research sites in the United States, Europe and Australia. Across the wider research programme, patient experience exceeded one million hours. These devices remain investigational, and commercial distribution requires regulatory evaluation and approval.

The FY26 result also described investment in referral pathways for adults with severe hearing loss. Cochlear Limited (ASX:COH) is working with clinical professionals and healthcare systems to improve progression from hearing assessment to implant surgery. Management announced measures to reduce fixed costs and redirect resources toward medical engagement, product development and digital support tools.

Financial Performance and Sector Context

For the year ended June 2026, Cochlear Limited (ASX:COH) recorded sales revenue of AUD 2,343.4 million versus AUD 2,355.8 million in FY25, a reported decline of 1% but growth of 2% at constant currency. Underlying net profit decreased from AUD 414.5 million to AUD 322.4 million, while statutory net profit declined from AUD 388.9 million to AUD 147.3 million.

FY26 cochlear implant revenue was AUD 1,435.2 million, with unit volumes increasing 5% to 56,692. Services revenue reached AUD 634.9 million and Acoustics revenue was AUD 273.3 million. Gross margin contracted from 74% to 71%, reflecting product and geographic mix, lower manufacturing overhead recovery and currency effects. Research and development expenses increased 15% to AUD 323.2 million.

Operating cash flow rose to AUD 368.0 million from AUD 237.6 million, and free cash flow reached AUD 263.5 million. Net cash at June 2026 was AUD 187.7 million, compared with AUD 275.7 million a year earlier. FY26 ordinary dividends totalled AUD 3.45 per share, compared with AUD 4.30 in FY25.

Sector conditions differ across regions. Cochlear cited hospital backlogs and industrial action affecting procedures in parts of Western Europe, while pricing reductions in China influenced emerging-market revenue. Referral pathways, insurance approvals and regional healthcare access remain material considerations for hearing-implant demand.

Risks to Consider

Cochlear Limited (ASX:COH) faces exposure to reimbursement and procurement changes, procedure delays, currency movements, manufacturing utilisation and competing implant products. Development-stage technologies also carry clinical and regulatory risks. FY26 included AUD 66.0 million of after-tax cloud computing expenses and AUD 109.1 million in non-cash investment-related losses, illustrating the distinction between underlying and statutory earnings.

What to Watch Next

For FY27, Cochlear stated guidance of low single-digit constant-currency sales growth and underlying net profit of AUD 330–350 million. The outlook assumes a gross margin around 70–71%, research expenditure near 13% of sales and capital spending of AUD 100–110 million. The 26 October 2026 annual general meeting, subsequent reporting periods, Osia 3 rollout and further clinical-study data are identifiable milestones.

Key Insights

Cochlear Limited (ASX:COH) entered FY27 after a year of higher implant unit sales, lower reported revenue and reduced profit margins. Cash generation improved, while clinical research and referral initiatives continued. Financial reporting, regional demand, cost changes and regulatory progress provide measurable points for tracking the business without attributing the daily share-price change to earlier company announcements.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.